Drug Profile
Research programme: PARP inhibitors - AbbVie
Alternative Names: A-620223; A-866111; ABT-472; ABT-880698; ABT-887563Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Benzimidazoles
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer